Cargando…
R&D Incentives for Neglected Diseases
Neglected diseases are typically characterized as those for which adequate drug treatment is lacking, and the potential return on effort in research and development (R&D), to produce new therapies, is too small for companies to invest significant resources in the field. In recent years various i...
Autor principal: | Dimitri, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526606/ https://www.ncbi.nlm.nih.gov/pubmed/23284648 http://dx.doi.org/10.1371/journal.pone.0050835 |
Ejemplares similares
-
Effectiveness of R&D Tax Incentives in Turkey
por: Taş, Ekin, et al.
Publicado: (2023) -
Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?
por: Mueller-Langer, Frank
Publicado: (2013) -
Incentives for Reporting Disease Outbreaks
por: Laxminarayan, Ramanan, et al.
Publicado: (2014) -
The Effect of Incentives and Meta-incentives on the Evolution of Cooperation
por: Okada, Isamu, et al.
Publicado: (2015) -
Pharmaceutical Enterprises’ R&D Innovation Cooperation Moran Strategy When Considering Tax Incentives
por: Xu, Yanping, et al.
Publicado: (2022)